Adempas Dosing
Start Adempas at 1 mg three times daily (or 0.5 mg three times daily if hypotension is a concern), then titrate by 0.5 mg increments every 2 weeks based on blood pressure tolerance, up to a maximum of 2.5 mg three times daily. 1
Standard Dosing and Titration
The FDA-approved dosing regimen for riociguat follows an individualized titration protocol 1:
- Starting dose: 1 mg three times daily
- Alternative starting dose: 0.5 mg three times daily for patients who may not tolerate hypotensive effects
- Titration schedule: Increase by 0.5 mg three times daily every 2 weeks
- Titration criteria: Only increase if systolic blood pressure remains >95 mmHg AND patient has no signs/symptoms of hypotension
- Maximum dose: 2.5 mg three times daily
- Dose reduction: Decrease by 0.5 mg three times daily if hypotension symptoms occur at any time
This dose-adjustment scheme allows optimization for both tolerability and efficacy, with the majority of patients in phase III trials achieving the maximum dose 2. The guideline evidence supports that riociguat requires dose titration as part of its therapeutic approach 3.
Special Populations and Adjustments
Hepatic Impairment
No dose adjustment is needed for mild hepatic impairment (Child-Pugh A), but exercise particular caution with dose titration in moderate hepatic impairment (Child-Pugh B). Research demonstrates that riociguat exposure increases by approximately 53% in Child-Pugh B patients compared to controls, with prolonged half-life of the metabolite M1 4. While the FDA label doesn't mandate specific dose reductions, the pharmacokinetic data support more conservative titration in these patients.
Renal Impairment
No specific dose adjustment is required for renal impairment, though exposure is variable and overlaps with healthy controls. Despite reduced renal clearance and prolonged half-life in patients with renal impairment, the relationship between creatinine clearance and riociguat exposure is not strictly proportional 5. The standard titration protocol based on blood pressure tolerance remains appropriate.
Smokers
Consider titrating above 2.5 mg three times daily (if tolerated) in patients who smoke, and reduce dose if patients stop smoking. 1 Tobacco smoke induces CYP1A1, one of riociguat's metabolizing enzymes, leading to increased clearance 4, 5. This is a critical but often overlooked adjustment.
Drug Interactions and Contraindications
Strong CYP and P-gp/BCRP Inhibitors
Start at 0.5 mg three times daily when initiating riociguat in patients on strong inhibitors (azole antifungals like ketoconazole/itraconazole, or HIV protease inhibitors like ritonavir). Monitor closely for hypotension 1.
PDE5 Inhibitor Interactions (Critical Contraindication)
Riociguat is absolutely contraindicated with concomitant PDE5 inhibitor use due to severe hypotension risk 3, 1:
- Discontinue sildenafil ≥24 hours before starting riociguat
- Discontinue tadalafil ≥48 hours before starting riociguat
- Discontinue riociguat ≥24 hours before starting any PDE5 inhibitor
- Consider 0.5 mg starting dose in patients at hypotension risk when transitioning
- Counsel male patients: Do not use PDE5 inhibitors for erectile dysfunction while on riociguat
Real-world data confirms physicians generally follow these washout periods, though slightly longer periods are used for tadalafil in practice 6.
Dosing Interruption
If riociguat is interrupted for ≥3 days, restart the full titration protocol from the beginning. If a single dose is missed, simply continue with the next scheduled dose 1.
Administration
For patients unable to swallow tablets, riociguat may be crushed and mixed with water or soft foods (like applesauce) immediately before administration 1.
REMS Program Requirements
All female patients require enrollment in the Adempas REMS Program due to embryo-fetal toxicity risk 1:
- Pregnancy testing before treatment initiation
- Monthly pregnancy testing during treatment
- Pregnancy testing 1 month after discontinuation
- Mandatory effective contraception during treatment and for 1 month after
Clinical Context
The 2014 CHEST guidelines suggest riociguat for WHO functional class II and III PAH patients to improve 6-minute walk distance, WHO functional class, delay clinical worsening, and improve cardiopulmonary hemodynamics 3. The dose titration requirement distinguishes riociguat from other oral PAH therapies (ERAs and PDE5 inhibitors), which are typically initiated at fixed approved doses.
Common pitfall: Failing to adequately assess blood pressure before each dose escalation. The titration is not time-based alone—it requires both the 2-week interval AND confirmation of adequate blood pressure tolerance.